Showing results (691-700 of 1,188) with videos related to

Sort By:
Pageof 119
Annals of Hematology|February 2, 2020
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?Wei Xie, Guiling Tang, Endi Wang, et al.
American Journal of Hematology|November 5, 2014
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemiaTapan M Kadia, Hagop M Kantarjian, Deborah A Thomas, et al.
British Journal of Haematology|July 1, 2015
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosisSanam Loghavi, Alyaa Al-Ibraheemi, Zhuang Zuo, et al.
Blood|October 16, 2004
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasStefan Faderl, Varsha Gandhi, Susan O'Brien, et al.
Blood|August 15, 2002
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Cancer|November 20, 2019
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemiaKoji Sasaki, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, et al.
Frontiers in Oncology|May 27, 2021
Immunotherapy in Acute Myeloid Leukemia: Where We StandAlessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Future Oncology (London, England)|January 20, 2016
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaGail J Roboz, Pau Montesinos, Dominik Selleslag, et al.
Leukemia & Lymphoma|September 5, 2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemiaYue Wei, Hong Zheng, Pamela Pennington Lockyer, et al.
Blood Advances|October 3, 2018
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in miceYue Wei, Hong Zheng, Naran Bao, et al.
Pageof 119